One of the primary PD-1 inhibitors in use today is pembrolizumab (Table 1), a selective humanized IgG4 kappa anti-PD-1 monoclonal antibody that has shown therapeutic benefit in the treatment of multiple types of cancers [41,42]. The gene discussed is PDCD1; the disease is cancer.